Illumina (NASDAQ:ILMN) Director Keith Meister Sells 457,858 Shares of Stock

Posted by Brenda Bartman on Aug 7th, 2026

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Illumina Stock Down 3.1%

Shares of Illumina stock opened at $193.72 on Friday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The company has a 50 day moving average of $180.63 and a 200 day moving average of $148.77. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $29.25 billion, a P/E ratio of 36.14, a P/E/G ratio of 2.81 and a beta of 1.45.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the firm posted $1.19 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of a number of analyst reports. Canaccord Genuity Group raised their price target on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday. Royal Bank Of Canada upped their price objective on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Guggenheim increased their price objective on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a report on Friday, July 31st. Stifel Nicolaus raised their target price on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and an average price target of $188.40.

View Our Latest Research Report on Illumina

Illumina News Summary

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Zacks upgraded Illumina from “hold” to “strong buy,” citing favorable momentum characteristics. The company has also benefited from strong clinical momentum and continued leadership in genomic sequencing. Why Illumina Is a Strong Momentum Stock
Positive Sentiment: Piper Sandler reiterated an “overweight” rating, while TD Cowen maintained its “hold” rating. The mixed views indicate some analysts remain constructive on Illumina’s longer-term opportunity despite near-term concerns. Piper Sandler Reiterates Overweight Rating
Neutral Sentiment: Illumina’s recent earnings showed revenue growth and an EPS beat, but investors remain focused on the sustainability of demand and whether growth can justify the stock’s elevated valuation following its strong 52-week advance.
Negative Sentiment: Director Keith A. Meister sold approximately 741,000 Illumina shares across August 4 and 5 for a combined value of about $148.2 million, reducing his holdings by roughly 28% over the two transactions. Although he still owns more than 2 million shares, the large sales may weigh on investor sentiment. Illumina Insider Trading Filing
Negative Sentiment: Bank of America Securities reiterated a “sell” rating and a $140 price target, arguing that a one-time consumables benefit is masking weak underlying demand. The target is substantially below recent trading levels, reinforcing concerns about near-term operating momentum. Bank of America Maintains Sell Rating on Illumina

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Elyxium Wealth LLC acquired a new position in Illumina in the fourth quarter valued at $25,000. Creative Capital Management Investments LLC increased its position in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the 4th quarter valued at about $26,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the 4th quarter valued at about $26,000. Finally, Elevation Wealth Partners LLC boosted its position in shares of Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.